Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities (2016 - 2025)

Fennec Pharmaceuticals' Total Non-Current Liabilities history spans 13 years, with the latest figure at $24.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 44.05% year-over-year to $24.6 million, compared with a TTM value of $24.6 million through Dec 2025, down 44.05%, and an annual FY2025 reading of $24.6 million, down 44.05% over the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $24.6 million at Fennec Pharmaceuticals, down from $43.9 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $56.8 million in Q2 2024, with the low at $4.0 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $30.3 million, with a median of $25.5 million recorded in 2023.
  • Year-over-year, Total Non-Current Liabilities surged 536.24% in 2023 and then tumbled 44.05% in 2025.
  • Tracing FENC's Total Non-Current Liabilities over 5 years: stood at $5.0 million in 2021, then surged by 399.28% to $24.9 million in 2022, then increased by 24.23% to $30.9 million in 2023, then surged by 41.92% to $43.9 million in 2024, then tumbled by 44.05% to $24.6 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Total Non-Current Liabilities are $24.6 million (Q4 2025), $43.9 million (Q3 2025), and $43.9 million (Q2 2025).